Loading...

"Infertility and the loss of bone density are minuscule prices to pay compared with the risk of suicide for trans patients who are blocked..."

Loading...
"Infertility and the loss of bone density are minuscule prices to pay compared with the risk of suicide for trans patients who are blocked..." - Hallo friend WELCOME TO AMERICA, In the article you read this time with the title "Infertility and the loss of bone density are minuscule prices to pay compared with the risk of suicide for trans patients who are blocked...", we have prepared well for this article you read and download the information therein. hopefully fill posts Article AMERICA, Article CULTURAL, Article ECONOMIC, Article POLITICAL, Article SECURITY, Article SOCCER, Article SOCIAL, we write this you can understand. Well, happy reading.

Title : "Infertility and the loss of bone density are minuscule prices to pay compared with the risk of suicide for trans patients who are blocked..."
link : "Infertility and the loss of bone density are minuscule prices to pay compared with the risk of suicide for trans patients who are blocked..."

see also


"Infertility and the loss of bone density are minuscule prices to pay compared with the risk of suicide for trans patients who are blocked..."

"... by doctors, parents or legislators from accessing gender-affirming treatment. There are many medical interventions with potentially life-altering side effects. Why are gender-affirming treatments for trans individuals being singled out as uniquely dangerous and worthy of public scrutiny?"

Writes a transgender woman, in one of the letters to the NYT responding to the article "They Paused Puberty, but Is There a Cost?/Puberty blockers can ease transgender youths’ anguish and buy time to weigh options. But concerns are growing about long-term physical effects and other consequences" (which we discussed on this blog, here).

Another one of the letters gives a good answer to the question she asks. This is from Marc B. Garnick, a professor at Harvard Medical School and Beth Israel Deaconess Medical Center:

As one of three academic principal clinical investigators of studies that led to the initial F.D.A. approval of Lupron for the treatment of metastatic prostate cancer — and having studied this class of drugs, which includes puberty blockers, for more than four decades — I can say that physicians are still learning and continue to be concerned about the safety of these agents in adults.

Woefully little safety data are available for the likely more vulnerable younger population. Bone loss in adult men who have been on these agents is significant, and a leading cause of morbidity with long-term administration.

Other safety issues include cognitive, metabolic and cardiovascular effects, still under intense investigation. The prudent and ethical use of such agents in the younger population should demand that every pubertal or pre-pubertal child be part of rigorous clinical research studies that evaluate both the short-term and longer-term effects of these agents to better define the true risks and benefits rather than relying on anecdotal information.

Loading...
"... by doctors, parents or legislators from accessing gender-affirming treatment. There are many medical interventions with potentially life-altering side effects. Why are gender-affirming treatments for trans individuals being singled out as uniquely dangerous and worthy of public scrutiny?"

Writes a transgender woman, in one of the letters to the NYT responding to the article "They Paused Puberty, but Is There a Cost?/Puberty blockers can ease transgender youths’ anguish and buy time to weigh options. But concerns are growing about long-term physical effects and other consequences" (which we discussed on this blog, here).

Another one of the letters gives a good answer to the question she asks. This is from Marc B. Garnick, a professor at Harvard Medical School and Beth Israel Deaconess Medical Center:

As one of three academic principal clinical investigators of studies that led to the initial F.D.A. approval of Lupron for the treatment of metastatic prostate cancer — and having studied this class of drugs, which includes puberty blockers, for more than four decades — I can say that physicians are still learning and continue to be concerned about the safety of these agents in adults.

Woefully little safety data are available for the likely more vulnerable younger population. Bone loss in adult men who have been on these agents is significant, and a leading cause of morbidity with long-term administration.

Other safety issues include cognitive, metabolic and cardiovascular effects, still under intense investigation. The prudent and ethical use of such agents in the younger population should demand that every pubertal or pre-pubertal child be part of rigorous clinical research studies that evaluate both the short-term and longer-term effects of these agents to better define the true risks and benefits rather than relying on anecdotal information.



Thus articles "Infertility and the loss of bone density are minuscule prices to pay compared with the risk of suicide for trans patients who are blocked..."

that is all articles "Infertility and the loss of bone density are minuscule prices to pay compared with the risk of suicide for trans patients who are blocked..." This time, hopefully can provide benefits to all of you. Okay, see you in another article posting.

You now read the article "Infertility and the loss of bone density are minuscule prices to pay compared with the risk of suicide for trans patients who are blocked..." with the link address https://welcometoamerican.blogspot.com/2022/11/infertility-and-loss-of-bone-density.html

Subscribe to receive free email updates:

0 Response to ""Infertility and the loss of bone density are minuscule prices to pay compared with the risk of suicide for trans patients who are blocked...""

Post a Comment

Loading...